JCI:新药Vorinostat使潜伏的HIV暴露更彻底,治疗取得重大进展!

2017-07-18 sunshine2015 来宝网

北卡罗来纳大学教堂山大学的研究人员已经表明,药物Vorinostat的间歇给药可以逆转艾滋病病毒,并且对艾滋病毒感染者的耐受性良好。然而,虽然Vorinostat使潜在的艾滋病毒易于检测,但它不能清除或消除感染,这意味着需要额外的进步来实现治愈。这些结果发表在7月17日的“临床调查杂志”上。

【研究加快了暴露潜在HIV的能力】暴露出艾滋病病毒库,以便清除艾滋病毒,这是一项战略,正在努力开发治疗全球近4000万艾滋病毒感染者的治疗方法。北卡罗来纳大学教堂山大学的研究人员已经表明,药物Vorinostat的间歇给药可以逆转艾滋病病毒,并且对艾滋病毒感染者的耐受性良好。然而,虽然Vorinostat使潜在的艾滋病毒易于检测,但它不能清除或消除感染,这意味着需要额外的进步来实现治愈。这些结果发表在7月17日的“临床调查杂志”上。

该小组研究了Vorinostat在16名感染艾滋病毒的患者病毒载量通过标准抗病毒治疗进行控制。以48或72小时的间隔施用Vorinostat的剂量。该小组发现,即使维持血液中病毒载量的控制,Vorinostat每三天施用一次即可在潜伏感染的CD4 + T细胞内更容易发现艾滋病毒。

Nancie Archin Ph.D说:“我们表明,单剂量的Vorinostat可以在几年前暴露隐藏的病毒,但是在过去五年中已经进行了两项研究,以确定适当的间隔给药策略来安全有效地使用Vorinostat。该研究的主要作者和UNC传染病司助理教授说 “现在我们可以试图削减病毒库。”

用Vorinostat治疗一个月以上,几乎没有副作用,没有发现严重的毒副作用,但没有发现潜伏感染的消耗。该团队认为,将Vorinostat等潜伏逆转剂与抗病毒免疫治疗(例如疫苗或能够识别和清除潜在细胞的抗体)配对将可能实现治愈。

“我们现在已经开始了两项小型,深入研究,将Vorinostat与Argos Therapeutics生产的抗艾滋病毒疫苗配对,或者由Cath Bollard在儿童国家医疗中心实验室制备的抗病毒免疫细胞的输注,联合国艾滋病毒/艾滋病毒全球卫生和传染病研究所的UNC艾滋病毒治疗中心主任David Margolis说道。 “我们不希望立即取得成功,但希望在开展治疗方面取得进展,有一天可能会清除艾滋病毒感染。”

原始出处:Nancie M. Archin, Jennifer L. Kirchherr, Julia A.M. Sung, et al.Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency, JCI. July 17, 2017

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1814517, encodeId=4142181451e58, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 03 05:26:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982073, encodeId=a25e19820e302, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 11 18:26:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223563, encodeId=09592235636f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jul 18 13:44:55 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223546, encodeId=f69722354639, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jul 18 13:20:58 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223537, encodeId=da2c22353e19, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Jul 18 12:37:40 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223536, encodeId=55702235360d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Jul 18 12:34:07 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1814517, encodeId=4142181451e58, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 03 05:26:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982073, encodeId=a25e19820e302, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 11 18:26:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223563, encodeId=09592235636f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jul 18 13:44:55 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223546, encodeId=f69722354639, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jul 18 13:20:58 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223537, encodeId=da2c22353e19, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Jul 18 12:37:40 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223536, encodeId=55702235360d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Jul 18 12:34:07 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1814517, encodeId=4142181451e58, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 03 05:26:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982073, encodeId=a25e19820e302, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 11 18:26:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223563, encodeId=09592235636f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jul 18 13:44:55 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223546, encodeId=f69722354639, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jul 18 13:20:58 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223537, encodeId=da2c22353e19, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Jul 18 12:37:40 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223536, encodeId=55702235360d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Jul 18 12:34:07 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 楠博One

    学习谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1814517, encodeId=4142181451e58, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 03 05:26:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982073, encodeId=a25e19820e302, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 11 18:26:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223563, encodeId=09592235636f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jul 18 13:44:55 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223546, encodeId=f69722354639, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jul 18 13:20:58 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223537, encodeId=da2c22353e19, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Jul 18 12:37:40 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223536, encodeId=55702235360d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Jul 18 12:34:07 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 Y—xianghai

    学习了新知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1814517, encodeId=4142181451e58, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 03 05:26:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982073, encodeId=a25e19820e302, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 11 18:26:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223563, encodeId=09592235636f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jul 18 13:44:55 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223546, encodeId=f69722354639, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jul 18 13:20:58 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223537, encodeId=da2c22353e19, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Jul 18 12:37:40 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223536, encodeId=55702235360d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Jul 18 12:34:07 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 1e0ece0dm09(暂无匿称)

    谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1814517, encodeId=4142181451e58, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 03 05:26:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982073, encodeId=a25e19820e302, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 11 18:26:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223563, encodeId=09592235636f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jul 18 13:44:55 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223546, encodeId=f69722354639, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jul 18 13:20:58 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223537, encodeId=da2c22353e19, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Jul 18 12:37:40 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223536, encodeId=55702235360d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Jul 18 12:34:07 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 李东泽

    很好,不错,以后会多学习

    0

相关资讯

柳叶刀:HIV病毒携带者人群中的烟草使用

HIV病毒携带者使用烟草会导致其发病率和死亡率的上升。然而,对于低收入和中等收入国家(LMICs)的HIV病毒携带者人群的烟草使用情况,我们知之甚少。来自美国约克大学的研究者开展研究评估了在中低收入国家中HIV携带者的烟草使用情况。研究使用了从2003年至2014年收集的28个LMICs国家的人口和健康调查数据,其中包括了烟草的使用数据和HIV病毒检测数据。研究估计了国家间、地区间以及总体的烟草使

Neurology:乌干达周围神经病变以及风险因素研究

周围神经病变在乌干达农村的成年人中比较常见并且与功能性疾病相关。年龄、女性和HIV感染显著增加神经病变的风险

美国国立卫生研究院:你知道吗?受到了细胞信号,HIV才会感染

来自美国国立卫生研究院的一项新的研究已经识别出了一个至关重要的阶段在HIV感染过程中,病毒将遗传物质导入健康细胞。 这一发现可能最终导致治疗在早期阶段上阻止HIV传播。

HIV自我检测试剂盒:使HIV诊断更快捷!

来自UCL,伦敦卫生和热带医学学院和英国公共卫生学院的一项新研究旨在发现是否向男性提供免费的艾滋病毒自我检测,与男性发生性关系的变性男性和变性妇女可以减少未诊断的HIV。

RETROVIROLOGY :人类基因组中很早之前就已经植入了抗击HIV的病毒!

在我们的演变过程中,病毒像今天一样,不断地感染人类。一些早期病毒融入我们的基因组,现在被称为人内源性逆转录病毒(HERV)。数百万年来,由于其遗传密码中的突变或重大缺失,它们变得惰性。目前,研究最多的HERV家族之一是HERV-K家族,自从人类和黑猩猩进化分裂以来,HERV-K家族已经活跃,有些成员可能在过去几十万年内积极地感染人类。

J EXP MED:自身免疫疾病障碍会大大增加感染HIV的几率

科罗拉多大学医学院的研究人员发现,保护人体免受自身免疫性疾病感染的过程,也会阻止免疫系统产生能中和HIV- 1病毒的抗体。。这项研究结果将于7月11日发表在《实验医学杂志》上,科学家们可能会考虑研制一种能够刺激这些中和抗体产生的疫苗。